Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftaroline Fosamil

FDA-approved product (powder, intravenous), marketed as Ceftaroline Fosamil, Teflaro.

Registered studies
50+
Lab records
19
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftaroline Fosamil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cephalosporins and penems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DI02

Repurposing investigation

Ceftaroline Fosamil is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA75.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli74.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae92.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 13 of 19 lab records
Open Ceftaroline Fosamil in ChEMBL Registered studies below
Show the 19 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftaroline Fosamil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia

    NCT01700842 · start 2012-10

    Registered record
    Registry ID
    NCT01700842
    Conditions
    Bacterial Skin Diseases
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10
    Completion
    2012-12
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Skin Diseases
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

    NCT01530763 · start 2012-09

    Registered record
    Registry ID
    NCT01530763
    Conditions
    Infections; Community Acquired Pneumonia
    Interventions
    Ceftaroline fosamil; Ceftriaxone; amoxicillin clavulanate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-07
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections; Community Acquired Pneumonia
    InterventionCeftaroline fosamil; Ceftriaxone; amoxicillin clavulanate
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects

    NCT01612507 · start 2012-07

    Registered record
    Registry ID
    NCT01612507
    Conditions
    Healthy Volunteers
    Interventions
    600 mg Ceftaroline fosamil; Placebo; 600 mg Ceftaroline fosamil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-11
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Intervention600 mg Ceftaroline fosamil; Placebo; 600 mg Ceftaroline fosamil; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of Ceftaroline in Normal and Obese Subjects

    NCT01648127 · start 2012-07

    Registered record
    Registry ID
    NCT01648127
    Conditions
    Drug Safety
    Interventions
    Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Safety
    InterventionCeftaroline
    PhasePhase 1
    Registry statusCompleted

  • Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

    NCT01605864 · start 2012-05

    Registered record
    Registry ID
    NCT01605864
    Conditions
    Community Acquired Bacterial Pneumonia
    Interventions
    Efficacy of ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2013-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Bacterial Pneumonia
    InterventionEfficacy of ceftaroline
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance

    NCT01624246 · start 2012-05

    Registered record
    Registry ID
    NCT01624246
    Conditions
    Augmented Renal Clearance (ARC); Systemic Inflammatory Response Syndrome (SIRS)
    Interventions
    Ceftaroline fosamil/Avibactam (CXL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05
    Completion
    2013-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAugmented Renal Clearance (ARC); Systemic Inflammatory Response Syndrome (SIRS)
    InterventionCeftaroline fosamil/Avibactam (CXL)
    PhasePhase 1
    Registry statusCompleted

  • A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects

    NCT01577589 · start 2012-04

    Registered record
    Registry ID
    NCT01577589
    Conditions
    Healthy
    Interventions
    600 mg ceftaroline fosamil in 50 ml infusion volume; Placebo in 50 ml infusion volume; 600 ceftaroline fosamil in 250 ml infusion volume; Placebo in 250 ml infusion volume; 600 mg ceftaroline in 100 ml infusion volume; Placebo in 100 ml infusion volume
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-09
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention600 mg ceftaroline fosamil in 50 ml infusion volume; Placebo in 50 ml infusion volume; 600 ceftaroline fosamil in 250 ml infusion volume; Placebo in 250 ml infusion volume +2 more
    PhasePhase 1
    Registry statusCompleted

  • Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

    NCT02582203 · start 2012-02

    Registered record
    Registry ID
    NCT02582203
    Conditions
    Skin Diseases, Infectious; Staphylococcal Skin Infections
    Interventions
    Ceftaroline; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2016-05
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious; Staphylococcal Skin Infections
    InterventionCeftaroline; Vancomycin
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

    NCT01371838 · start 2011-12

    Registered record
    Registry ID
    NCT01371838
    Conditions
    Community-Acquired Bacterial Pneumonia; Lung Infection of Individual Not Recently Hospitalized
    Interventions
    Ceftaroline; Ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-05
    Enrolment
    848

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-Acquired Bacterial Pneumonia; Lung Infection of Individual Not Recently Hospitalized
    InterventionCeftaroline; Ceftriaxone
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

    NCT01400867 · start 2011-12

    Registered record
    Registry ID
    NCT01400867
    Conditions
    Infections, Pediatrics
    Interventions
    Ceftaroline fosamil; Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Cephalexin or Clindamycin or Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-07
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Pediatrics
    InterventionCeftaroline fosamil; Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Cephalexin or Clindamycin or Linezolid
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Ceftaroline China Pharmacokinetics Study

    NCT01458743 · start 2011-10

    Registered record
    Registry ID
    NCT01458743
    Conditions
    Healthy
    Interventions
    Ceftaroline; Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCeftaroline; Ceftaroline
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

    NCT01734694 · start 2011-10

    Registered record
    Registry ID
    NCT01734694
    Conditions
    Health Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia; Acute Bacterial Skin and Skin Structure Infections
    Interventions
    Vancomycin; Ceftaroline; Daptomycin; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-10
    Completion
    2012-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia +1 more
    InterventionVancomycin; Ceftaroline; Daptomycin; Linezolid
    PhasePhase 4
    Registry statusTerminated

  • Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital

    NCT01298843 · start 2011-04

    Registered record
    Registry ID
    NCT01298843
    Conditions
    Infections
    Interventions
    Ceftaroline fosamil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-04
    Completion
    2013-02
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionCeftaroline fosamil
    PhasePhase 4
    Registry statusCompleted

  • A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

    NCT01290900 · start 2011-02

    Registered record
    Registry ID
    NCT01290900
    Conditions
    Healthy Male Volunteers
    Interventions
    NXL104; Ceftaroline; Placebo Infusion; Ceftazidime; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2011-05
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male Volunteers
    InterventionNXL104; Ceftaroline; Placebo Infusion; Ceftazidime +1 more
    PhasePhase 1
    Registry statusCompleted

  • Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

    NCT01281462 · start 2010-12

    Registered record
    Registry ID
    NCT01281462
    Conditions
    Urinary Tract Infections
    Interventions
    Ceftaroline fosamil and NXL104 (q8h); Ceftaroline fosamil and NXL104 (q12h); Doripenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-07
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCeftaroline fosamil and NXL104 (q8h); Ceftaroline fosamil and NXL104 (q12h); Doripenem; Placebo
    PhasePhase 2
    Registry statusCompleted